Intercept Pharmaceuticals (ICPT) PT Lowered to $22 at Needham & Company on "Concerns Around Overall Benefit/Safety Profile" of OCA
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $22.00 (from $25.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
